These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38306487)

  • 1. Non-KPC Attributes of Newer β-lactam/β-lactamase Inhibitors, Part 1: Enterobacterales and Pseudomonas aeruginosa.
    Fratoni AJ; Gethers ML; Nicolau DP; Kuti JL
    Clin Infect Dis; 2024 Jul; 79(1):33-42. PubMed ID: 38306487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activity of ceftazidime-avibactam against KPC-2-producing Enterobacterales: a cross-combination and dose-escalation titration study with relebactam and vaborbactam.
    Kang MS; Baek JY; Ko J-H; Cho SY; Lee KY; Lee YH; Yang J; Kim TY; Huh HJ; Lee NY; Huh K; Kang C-I; Chung DR; Peck KR
    Microbiol Spectr; 2024 Jun; 12(6):e0034424. PubMed ID: 38687076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
    Lee SY; Gill CM; Nicolau DP;
    J Antimicrob Chemother; 2023 Dec; 78(12):2795-2800. PubMed ID: 37840005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US medical centres (2020-2021).
    Sader HS; Mendes RE; Arends SJR; Carvalhaes CG; Shortridge D; Castanheira M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106744. PubMed ID: 36738849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals.
    Castanheira M; Doyle TB; Deshpande LM; Mendes RE; Sader HS
    Int J Antimicrob Agents; 2021 Nov; 58(5):106439. PubMed ID: 34547421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of aspergillomarasmine A/meropenem combinations with and without avibactam against bacterial strains producing multiple β-lactamases.
    Rotondo CM; Wright GD
    Antimicrob Agents Chemother; 2024 Sep; 68(9):e0027224. PubMed ID: 39133022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New β-Lactam-β-Lactamase Inhibitor Combinations.
    Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Basis of Class A β-Lactamase Inhibition by Relebactam.
    Tooke CL; Hinchliffe P; Lang PA; Mulholland AJ; Brem J; Schofield CJ; Spencer J
    Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C; Freire S; Nordmann P; Poirel L
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.
    Papp-Wallace KM; Barnes MD; Alsop J; Taracila MA; Bethel CR; Becka SA; van Duin D; Kreiswirth BN; Kaye KS; Bonomo RA
    Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
    Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
    J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant
    Zalacain M; Achard P; Llanos A; Morrissey I; Hawser S; Holden K; Toomey E; Davies D; Leiris S; Sable C; Ledoux A; Bousquet J; Castandet J; Lozano C; Everett M; Lemonnier M
    Antimicrob Agents Chemother; 2024 Mar; 68(3):e0112023. PubMed ID: 38289044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing the in vivo impact of novel β-lactamase inhibitors on the efficacy of their partner β-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures.
    Ruiz VH; Gill CM; Nicolau DP
    J Antimicrob Chemother; 2024 Mar; 79(3):546-551. PubMed ID: 38217443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deciphering variable resistance to novel carbapenem-based β-lactamase inhibitor combinations in a multi-clonal outbreak caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam.
    Di Pilato V; Principe L; Andriani L; Aiezza N; Coppi M; Ricci S; Giani T; Luzzaro F; Rossolini GM
    Clin Microbiol Infect; 2023 Apr; 29(4):537.e1-537.e8. PubMed ID: 36414199
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypes, genotypes and breakpoints: an assessment of β-lactam/ β-lactamase inhibitor combinations against OXA-48.
    Asempa TE; Kois AK; Gill CM; Nicolau DP
    J Antimicrob Chemother; 2022 Sep; 77(10):2622-2631. PubMed ID: 35325165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Minor Carbapenemases on Susceptibility to Novel β-Lactam/β-Lactamase Inhibitor Combinations and Cefiderocol in
    Sadek M; Bosch Duran J; Poirel L; Nordmann P
    Antimicrob Agents Chemother; 2023 May; 67(5):e0007823. PubMed ID: 37039645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meropenem-nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model.
    Asempa TE; Motos A; Abdelraouf K; Bissantz C; Zampaloni C; Nicolau DP
    Int J Antimicrob Agents; 2020 Feb; 55(2):105838. PubMed ID: 31705960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS; Castanheira M; Duncan LR; Mendes RE
    Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.